A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020.
Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile".
In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes.
Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial.
However, no new safety signals were observed in the study, Pfizer said.
Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini
Pfizer, REUTERS, Zepbound, Thomson
Manhattan, New York City , New York, U.S, Bengaluru, New York